Provexis plc

Equities

PXS

GB00B0923P27

Food Processing

Market Closed - London S.E. 11:35:08 2024-04-26 am EDT 5-day change 1st Jan Change
0.6 GBX 0.00% Intraday chart for Provexis plc 0.00% -7.69%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Quiz sales fall, names new CEO; Byotrol eyes AIM exit AN
Provexis plc Reports Earnings Results for the Half Year Ended September 30, 2023 CI
EARNINGS: Ebiquity swings to profit; SDX Energy swings to loss AN
Provexis plc Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Provexis notes regulatory filing for Fruitflow in China AN
Provexis' Local Partner Files for New Health Function Claim for Foods in China; Rises 12% MT
Redx confirms Jounce deal lapses, Tirupati seals deal AN
EARNINGS SUMMARY: Provexis and Unicorn Mineral post chunkier losses AN
Provexis plc Reports Earnings Results for the Half Year Ended September 30, 2022 CI
UK shareholder meetings calendar - next 7 days AN
UK shareholder meetings calendar - next 7 days AN
UK shareholder meetings calendar - next 7 days AN
UK shareholder meetings calendar - next 7 days AN
UK shareholder meetings calendar - next 7 days AN
Provexis plc Announces Directorate Change CI
Earnings Flash (PXS.L) PROVEXIS Reports FY22 Loss GBX-0.01 MT
Earnings Flash (PXS.L) PROVEXIS Posts FY22 Revenue GBP426,168 MT
Provexis plc Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Provexis plc Auditor Raises 'Going Concern' Doubt CI
Provexis, Enters into Alliance Agreement for Fruitflow® with Dsm Nutritional Products CI
Provexis plc Announces the Filing of New Patent Application CI
Earnings Flash (PXS.L) PROVEXIS Reports Fiscal H1 Revenue GBP211,195 MT
Earnings Flash (PXS.L) PROVEXIS Posts Fiscal H1 Loss GBX-0.01 MT
Provexis plc Reports Earnings Results for the Half Year Ended September 30, 2021 CI
Provexis plc Announces Agreement Between Provexis and By-Health for Supply of Fruitflow and Support in R&D CI
Chart Provexis plc
More charts
Provexis plc is engaged in developing, licensing and selling the proprietary, scientifically proven Fruitflow heart-health functional food ingredient. Fruitflow is a natural extract from tomatoes, which has been shown in human trials to reduce the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can lead to heart attack and stroke. The extract is available in two formats, a syrup and a spray-dried powder and can be included in a range of food, beverage, and dietary supplement formats. Fruitflow is a highly concentrated form of bioactives that is lycopene-free and contains over 30 known anti-platelet compounds. The syrup and powder versions of Fruitflow are GRAS in the United States. The Company also offers Fruitflow+ Omega-3, a dietary supplement product. The Company sells its Fruitflow+ Omega-3 dietary supplement product direct to consumers and serves its Chinese cross-border e-commerce distributor for this product in China.
More about the company
  1. Stock Market
  2. Equities
  3. PXS Stock
  4. News Provexis plc
  5. Earnings Flash (PXS.L) PROVEXIS Reports FY22 Loss GBX-0.01